Home » News » Urology » Overactive Bladder (OAB)
Overactive Bladder (OAB)
Gemtesa is an oral, once-daily, small molecule beta-3 adrenergic agonist.
Prevalence of nocturia reduced among postmenopausal women who selected systemic hormone therapy compared with no treatment
Extended-release tablets and extended-release oral suspension forms approved to treat neurogenic detrusor overactivity in children 3 years and older
Anticholinergics have been the main class of oral medications used to treat overactive bladder, but providers’ prescribing patterns have changed in light of research linking these medications to an increased risk for dementia, according to a new survey.
More attention should be focused on fall prevention for older adults with OAB dry, according to investigators.
Reducing dietary salt effectively improved both subjective and objective symptoms in patients with OAB who had excessive consumption of salt.
The placebo response is statistically, and possibly clinically, significant in patients with OAB, according to authors of a new systematic review.
In a real-world study, only half of patients continued with long-term maintenance percutaneous tibial nerve stimulation after the initial 12 weeks.
Responses to the OAB-BAT complement information from bladder diaries for monitoring overactive bladder outcomes, according to investigators.
Experiencing any urinary incontinence was associated with bother regardless of a man’s race.
Load More
Want to read more?
Please login or register first to view this content.
Login
Register
Open
Next post in Overactive Bladder (OAB)
Close
